An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis

Trial Profile

An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs ATA 188 Allogeneic (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 19 Oct 2017 Status changed from not yet recruiting to recruiting according to an Atara Bio media release.
    • 17 Oct 2017 According to an Atara Bio media release, US sites are expected to open for enrollment in 2018.
    • 16 Oct 2017 According to an Atara Bio media release, this trial is expected to initiate in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top